Under the partnership, patients in India will gain better access to clinical care as Clinerion’s Patient Network Explorer draws international clinical studies to the country.
Clinerion said that the patients will benefit most from participation in trials, by getting direct access to the Patient Network Explorer platform.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Additionally, they will benefit from the efficiencies created in the clinical research process by the platform which contributes to getting drugs quickly to market.
Efficiencies of Patient Network Explorer include accelerating study protocol development, identifying suitable trial sites, and speeding up patient search and identification for trial enrollment.
Alpha MD Life Sciences global head Dr Sanobar Parkar said: “Many approvals or new drug launches in the market are delayed due to slow recruitment, thus costing a lot of money to sponsors.
“In addition, even patients who can benefit from participation in a clinical trial, especially in the oncology field, miss the opportunity due to lack of awareness of available study protocols among treating physicians.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“By being part of this network, hospitals and patients in India will have access to global trials. This is necessary in making all alternatives available to patients and this will also eventually help in bringing new medicines to the Indian market and sooner.”
Earlier this month, Clinerion partnered with medical software company Sigmasoft to expand patient treatment options in Greece and Cyprus and bring access to international clinical studies for patients, physicians as well as healthcare institutions.
